Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Suarez, Fabio Enrique"'
Autor:
Ortiz Salas, Paola Andrea, Rodríguez, Jesús Hernán, Florez, Silvia Juliana Bueno, Suarez, Fabio Enrique
Publikováno v:
In Epilepsy Research September 2022 185
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Forero Suarez, Fabio Enrique
Publikováno v:
TDX (Tesis Doctorals en Xarxa).
OBJETIVO GENERAL Identificar, desde un enfoque fundamentado en la teoría crítica, las características espaciales que han antecedido y conllevado a la transformación (informalización?) de las primeras urbanizaciones populares modernas que constru
Externí odkaz:
http://hdl.handle.net/10803/386516
Autor:
Mutis Oviedo, Jorge Andrés
Publikováno v:
1.Van den Berg B, Walgaard C, Drenthen J, Fokke C, Jacobs BC, Van Doon PA. Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and progonosis. Nat. Rev. Neurol. 2014; 10 (8): 469 – 482.
2. Van Doorn PA.L & Jacobs, B.C. Clinical features, pathogenesis, and treatment of Guillain Barré syndrome. Lancet neurol. 2008; 7 (10):939-950
3. Hughes RAC, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2012; 11 (7).
4. Winer JB. Guillain-Barre syndrome. Mol Pathol. 2001; 54 (6) :381–385.
5. Mori M, Kuwabara S. Fisher Syndrome. Curr. Treat Options Neurol. 2011; 13 (1): 71-78.
6. Fokkin WJ, Selman MH, Dortland JR, Durmus B, Kuitwaard K, Huizinga R, et al. IgG fc N-glycosylation in Guillain Barré syndrome treated with inmunoglobulins. J. Proteome Res. 2014; 13 (3):1722 – 1730.
7. No author listed. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain Barré syndrome. Plasma exchange Sandoglobulin Guillain Barre syndrome Trial Group. Lancet. 1997; 349 (9047):225 – 230
8. Ansar V, Valadi N. Guillain Barré Syndrome. Prim Care. 2015; 42 (2):189-193.
9. Kuwabara S, Yuki N. Axonal Guillain Barré syndrome: concepts and controversies. Lancet Neurol. 2013; 12(12): 1180-1188
11. Van der Meché FG, Schmitz PI. A Randomized Trial Comparing Intravenous Immune Globulin and Plasma Exchange in Guillain-Barré Syndrome. Dutch Guillain Barré Study Group. N Engl J Med. 1992; 326 (17):1123-1129
12. Winters JL, Brown D, Hazard E, Chainani A, Andrzejewski C Jr. Cost-minimization analysis of the direct costs of TPE and IVIg in the treatment of Guillain-Barré syndrome. BMC Health Serv Res. 2011; 11:101.
13. Visser LH, Schmitz PI, Meulstee J, van Doorn PA, van der Meché FG. Prognostic factors of Guillain-Barré syndrome after intravenous immunoglobulin or plasma exchange. Dutch Guillain-Barré Study Group. Neurology. 1999; 53(3):598-604.
14. Banrep.gov.co (Internet). Colombia: Banco Central de la República de Coloombia; 2016. Disponible en: http://www.banrep.gov.co/es/trm
15. Hughes RA, Newson-Davis JM, Perkin GD, Pierce JM. Controlled trial prednisolone in acute polyneruopathy. Lancet. 1978; 2 (8093): 750-753.
16. Nagpal S, Benstead T, Shumak K, Rock G, Brown M, Anderson DR. Treatment of Guillain-Barré syndrome: a cost-effectiveness analysis. J Clin Apher. 1999; 14 (3): 107-13.
17. Tsai C, Wang K, Liu C, Sheng W, Lee T. Pharmacoeconomics of therapy for Guillain-Barré syndorme: plasma exchange and inravenous immunoglobulin, J Clin Neurosci. 2007; 14 (7): 625-629.
18. Oczko-Walker M, Manousakis G, Wang S, Malter JS, Waclawik AJ. Plasma exchange after initial intravenous immunoglobulin treatment in Guillain-Barré Syndrome: Critical reassessment of effectiveness and costo-efficiency. J clin neuromuscul dis. 2010; 12 (2), 55-61.
Repositorio EdocUR-U. Rosario
Universidad del Rosario
instacron:Universidad del Rosario
2. Van Doorn PA.L & Jacobs, B.C. Clinical features, pathogenesis, and treatment of Guillain Barré syndrome. Lancet neurol. 2008; 7 (10):939-950
3. Hughes RAC, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2012; 11 (7).
4. Winer JB. Guillain-Barre syndrome. Mol Pathol. 2001; 54 (6) :381–385.
5. Mori M, Kuwabara S. Fisher Syndrome. Curr. Treat Options Neurol. 2011; 13 (1): 71-78.
6. Fokkin WJ, Selman MH, Dortland JR, Durmus B, Kuitwaard K, Huizinga R, et al. IgG fc N-glycosylation in Guillain Barré syndrome treated with inmunoglobulins. J. Proteome Res. 2014; 13 (3):1722 – 1730.
7. No author listed. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain Barré syndrome. Plasma exchange Sandoglobulin Guillain Barre syndrome Trial Group. Lancet. 1997; 349 (9047):225 – 230
8. Ansar V, Valadi N. Guillain Barré Syndrome. Prim Care. 2015; 42 (2):189-193.
9. Kuwabara S, Yuki N. Axonal Guillain Barré syndrome: concepts and controversies. Lancet Neurol. 2013; 12(12): 1180-1188
11. Van der Meché FG, Schmitz PI. A Randomized Trial Comparing Intravenous Immune Globulin and Plasma Exchange in Guillain-Barré Syndrome. Dutch Guillain Barré Study Group. N Engl J Med. 1992; 326 (17):1123-1129
12. Winters JL, Brown D, Hazard E, Chainani A, Andrzejewski C Jr. Cost-minimization analysis of the direct costs of TPE and IVIg in the treatment of Guillain-Barré syndrome. BMC Health Serv Res. 2011; 11:101.
13. Visser LH, Schmitz PI, Meulstee J, van Doorn PA, van der Meché FG. Prognostic factors of Guillain-Barré syndrome after intravenous immunoglobulin or plasma exchange. Dutch Guillain-Barré Study Group. Neurology. 1999; 53(3):598-604.
14. Banrep.gov.co (Internet). Colombia: Banco Central de la República de Coloombia; 2016. Disponible en: http://www.banrep.gov.co/es/trm
15. Hughes RA, Newson-Davis JM, Perkin GD, Pierce JM. Controlled trial prednisolone in acute polyneruopathy. Lancet. 1978; 2 (8093): 750-753.
16. Nagpal S, Benstead T, Shumak K, Rock G, Brown M, Anderson DR. Treatment of Guillain-Barré syndrome: a cost-effectiveness analysis. J Clin Apher. 1999; 14 (3): 107-13.
17. Tsai C, Wang K, Liu C, Sheng W, Lee T. Pharmacoeconomics of therapy for Guillain-Barré syndorme: plasma exchange and inravenous immunoglobulin, J Clin Neurosci. 2007; 14 (7): 625-629.
18. Oczko-Walker M, Manousakis G, Wang S, Malter JS, Waclawik AJ. Plasma exchange after initial intravenous immunoglobulin treatment in Guillain-Barré Syndrome: Critical reassessment of effectiveness and costo-efficiency. J clin neuromuscul dis. 2010; 12 (2), 55-61.
Repositorio EdocUR-U. Rosario
Universidad del Rosario
instacron:Universidad del Rosario
Introducción: El Síndrome de Guillain Barré es considerado una de las principales causas de parálisis neuromuscular aguda. Actualmente existen dos alternativas igual de efectivas clínicamente en el tratamiento de esta enfermedad: la inmunoglobul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14ab9504177f710e74566a3dc867dc1a
http://repository.urosario.edu.co/handle/10336/20180
http://repository.urosario.edu.co/handle/10336/20180
